Lineage Cell Therapeutics, Inc. (LCTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LCTX POWR Grades
- LCTX scores best on the Growth dimension, with a Growth rank ahead of 81.62% of US stocks.
- LCTX's strongest trending metric is Momentum; it's been moving up over the last 179 days.
- LCTX ranks lowest in Stability; there it ranks in the 35th percentile.
LCTX Stock Summary
- Price to trailing twelve month operating cash flow for LCTX is currently 71.13, higher than 93.98% of US stocks with positive operating cash flow.
- With a price/sales ratio of 17.78, LINEAGE CELL THERAPEUTICS INC has a higher such ratio than 93.45% of stocks in our set.
- Revenue growth over the past 12 months for LINEAGE CELL THERAPEUTICS INC comes in at 295.58%, a number that bests 96.85% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to LINEAGE CELL THERAPEUTICS INC, a group of peers worth examining would be PTN, NBTX, ANGN, GLYC, and EXEL.
- LCTX's SEC filings can be seen here. And to visit LINEAGE CELL THERAPEUTICS INC's official web site, go to www.lineagecell.com.
LCTX Valuation Summary
- LCTX's price/sales ratio is 17.5; this is 733.33% higher than that of the median Healthcare stock.
- LCTX's price/sales ratio has moved down 68.1 over the prior 243 months.
Below are key valuation metrics over time for LCTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LCTX | 2023-01-30 | 17.5 | 3.1 | -5.0 | -4.7 |
| LCTX | 2023-01-27 | 17.1 | 3.0 | -4.9 | -4.5 |
| LCTX | 2023-01-26 | 16.8 | 3.0 | -4.8 | -4.5 |
| LCTX | 2023-01-25 | 18.3 | 3.2 | -5.2 | -4.9 |
| LCTX | 2023-01-24 | 18.3 | 3.2 | -5.2 | -4.9 |
| LCTX | 2023-01-23 | 17.9 | 3.2 | -5.1 | -4.8 |
LCTX Growth Metrics
- Its 4 year price growth rate is now at -68.62%.
- The 4 year net income to common stockholders growth rate now stands at -159.44%.
- Its 2 year cash and equivalents growth rate is now at 693.96%.
The table below shows LCTX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 13.956 | 3.489 | -48.909 |
| 2022-06-30 | 13.228 | 4.121 | -50.663 |
| 2022-03-31 | 9.187 | 5.767 | -48.688 |
| 2021-12-31 | 4.341 | -23.561 | -43.019 |
| 2021-09-30 | 3.528 | -23.329 | -11.995 |
| 2021-06-30 | 1.829 | -23.328 | -11.932 |
LCTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LCTX has a Quality Grade of D, ranking ahead of 12.26% of graded US stocks.
- LCTX's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
- INFI, ATHX, and TTNP are the stocks whose asset turnover ratios are most correlated with LCTX.
The table below shows LCTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.015 | 0.752 | -1.261 |
| 2021-03-31 | 0.015 | 0.763 | -0.860 |
| 2020-12-31 | 0.017 | 0.789 | -0.816 |
| 2020-09-30 | 0.024 | 0.855 | -0.706 |
| 2020-06-30 | 0.022 | 0.850 | -0.725 |
| 2020-03-31 | 0.023 | 0.859 | -1.019 |
LCTX Stock Price Chart Interactive Chart >
LCTX Price/Volume Stats
| Current price | $1.40 | 52-week high | $1.79 |
| Prev. close | $1.40 | 52-week low | $1.02 |
| Day low | $1.38 | Volume | 600,314 |
| Day high | $1.46 | Avg. volume | 333,995 |
| 50-day MA | $1.36 | Dividend yield | N/A |
| 200-day MA | $1.36 | Market Cap | 237.97M |
Lineage Cell Therapeutics, Inc. (LCTX) Company Bio
Lineage Cell Therapeutics, Inc. operates as a biotechnology company. The Company offers cell-based therapies and gene marker-based molecular diagnostics for diseases and degenerative conditions. Lineage Cell Therapeutics serves patients in the United States.
Latest LCTX News From Around the Web
Below are the latest news stories about LINEAGE CELL THERAPEUTICS INC that investors may wish to consider to help them evaluate LCTX as an investment opportunity.
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech ConferenceCARLSBAD, Calif., November 29, 2022--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the BTIG Virtual Ophthalmology Day, on November 29, 2022 at 12:00pm Eastern Time, in a fireside chat hosted by Yun Zhong, Ph.D., Director, Biotech Equity Research at BTIG. Mr. Culley will also be presenting at |
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationCARLSBAD, Calif., November 28, 2022--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that its partner Genentech, a member of the Roche Group, has launched a Phase 2a, multicenter, open-label, single arm clinical study of RG6501 (OpRegen), a retinal pigment epithelial cell therapy. The study is intended to optimize subretinal surgical delivery and evaluate the safet |
2 “Strong Buy” Penny Stocks That Could See 200% Gains (Or More)Investors know that the key to profits is in the return – and that means, a willingness to shoulder risk. Risk is relative, of course, and tends to run hand-in-hand with the return potential. Find a stock with a giant return potential, and chances are, you’ve also found one with a higher risk profile. The highest returns usually come along with the lowest share prices. After all, when a stock is priced for just pennies, even a small gain in share price translates into a huge return. |
What Makes Lineage Cell (LCTX) a New Buy StockLineage Cell (LCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Lineage Cell Therapeutics (LCTX) Receives a Buy from B.Riley FinancialIn a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Lineage Cell Therapeutics (LCTX - Research Report), with a price target of $4.00. The company's shares closed today at $1.31.Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -29.2% and a 22.86% success rate on recommended stocks. Lineage Cell Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.40, which is a 312.21% upside from current levels. |
LCTX Price Returns
| 1-mo | 13.82% |
| 3-mo | 6.87% |
| 6-mo | -18.13% |
| 1-year | -7.28% |
| 3-year | 38.61% |
| 5-year | -51.56% |
| YTD | 19.66% |
| 2022 | -52.24% |
| 2021 | 39.20% |
| 2020 | 97.75% |
| 2019 | -2.20% |
| 2018 | -57.67% |
Loading social stream, please wait...